Life Cycle Management Strategies - Optimizing revenues and defending generic competition

ReportsWeb.com has announced the addition of the “Global Life Cycle Management Strategies Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification.

GBI Research's latest report, "Life Cycle Management Strategies - Optimizing revenues and defending generic competition" discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on.

Companies mentioned in the report are AbbVie, Actavis, AstraZeneca, Cipla, Gilead, GlaxoSmithKline, Gleevec, Janssen, MannKind, Merck, Novartis, Orexo, Otsuka, Pfizer, Roche, Salix Pharmaceuticals, Sanofi-Aventis, Solvay, Teva and Vifor Pharma.

Request a Sample copy at http://www.reportsweb.com/life-cycle-management-strategies-optimizing-revenues-and-defending-generic-competition

Scope of the Report

- Introduction of LCM and product life cycle
- Objectives of LCM and factors impacting the choice of strategies
- LCM strategies depending on the way of approach
- Impact of LCM strategies on sales and growth trend of selected products
- Patent term extension and market exclusivity in the US and Europe
- LCM strategies of pipeline drugs of key players
- Keys to successful implementation of LCM strategies

Complete report is available at http://www.reportsweb.com/inquiry&RW0001170004/sample

- Identify the key LCM strategies used by most of the pharmaceutical companies
- Analyze the strategies to increase lifecycle and revenues of a drug
- Gain an understanding on the implementation of multiple strategies for a single product by including case studies
- Understand the operational pipeline strategies of key players

Executive Summary
Introduction
Overview of Product Life Cycle
Product Life Cycle Curve
Objectives of Life Cycle Management (LCM)
Classification and Benefits of LCM Strategies
Strategic Planning for LCM
Factors Impacting Choice of LCM Strategies
Developmental Strategies
Indication Expansion/Sequencing and Repositioning
Patient Subpopulations and Personalized Medicine
Reformulation
New Dosage Forms
New Route of Administration
Special Cases
New Dosage Strengths and Regimen
Fixed-Dose Combination and Co-packaging
Next Generation Products and Modified Chemistry
Metabolites
Chiral Switching
Polymorphs
Multiple Developmental Strategy Approach
Commercial Strategies
Rx-to-OTC/BTC Switch
Geographical Expansion
Pricing Strategy and Tactics
Pricing Strategy for Targeting Multiple Indications
Coupons
Co-pay Cards
Awareness, Brand Loyalty and Service Programs
Regulatory and Legal Strategies
Authorized Generics
Legal Defense and Pay for Delay
Citizen's Petition
Patent Term Extension and Market Exclusivity
The Pharmaceutical Pipeline and LCM
Successful Implementation of LCM Strategies
Appendix
Market Outlook
Key Market Players
Biosimilars Pipeline Analysis
Overview
By Stage of Development
By Molecule
By Therapy Area
By Indication
By MoA/RoA
Late-Stage Pipeline Biosimilars
Phase II Pipeline Biosimilars
Phase I Pipeline Biosimilars

Contact Us:                          
Call: +1-646-491-9876
Email: sales@reportsweb.com

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Pune:
505, 6th floor, Amanora Township,
Amanora Chambers, East Block,
Kharadi Road, Hadapsar, Pune-411028

This release was published on openPR.